昆明怀孕了做超导流产多少钱昆明哪所人流医院好,妇科在线咨询昆明台俪技,昆明做人流到那家医院比较好,昆明打胎手术价格表,昆明五十三天无痛打胎多少钱,昆明做人流哪个医院正规,昆明最好的妇产科医院排名第一

HAVANA, Sept. 6 (Xinhua) -- Cuban medical authorities have launched the sales of the world's first therapeutic vaccine against lung cancer, local officials said on Tuesday.The CimaVax-EGF vaccine, as a result of a 25-year research into diseases related to tobacco smoking, has been developed by researchers and scientists at the Center of Molecular Immunology (CIM) in Havana.The active drug ingredient in the vaccine is based on "a protein we all have when cancer is uncontrolled." "The epidermal growth factor is related to all cell proliferation," said Gisela Gonzalez, head researcher of the project."The drug could turn the cancer into a manageable, chronic disease by generating antibodies against the proteins which triggered the uncontrolled cell proliferation," she said.The immunogenic vaccine is appropriate to patients with advanced lung cancer in stages of three and four, showing no positive response to other kinds of treatments such as chemotherapy and radiotherapy, the expert said."It is not possible to prevent the disease but this vaccine improves significantly the status of the critically ill patients," she added.She said the CimaVax-EGF has gone through clinical studies and trials in over 1,000 patients across the island and is currently distributed free of charge in all hospitals of the Caribbean island nation.Gonzalez also said researchers at the CIM planned to use the same principle of the CimaVax-EGF in treating other cancerous tumors such as prostate, uterus and breast cancers.Lung cancer is regarded as one of the world's most serious, common and deadly cancers and is most frequently found among tobacco smokers.According to the World Health Organization, the disease generally kills 5 million people a year, and the figure is expected to rise to as much as 8 million by 2030 unless smoking habits are changed.In Cuba, like many other developing countries across the world, smoking is seen as a status symbol. Lung cancer, killing about 20,000 people a year in the Caribbean country, is considered a serious threat to public health and the leading cause of death in 12 of the country's 15 provinces.

BEIJING, Sept. 26 (Xinhuanet) -- Fu Ming'ai was reunited with his family on Sunday after 22 years.He is one of the more than 1,400 abducted children who were helped by a national DNA database, which helps match trafficked children and their parents."This shows the superiority of the national database," Chen Shiqu, director of the Ministry of Public Security's anti-human trafficking office, said on Sunday. The database was established in April 2009, when the ministry launched a nationwide crackdown on human trafficking."The ministry's branches across the country have been ordered to take blood samples of unidentified children and enter the information in the DNA database. Meanwhile, parents who report children missing also have their samples deposited in the repository," Chen said. "The database will point out matches for parents and children."DNA testing is accurate for both individual identification and kinship relations, and it is acknowledged as one of the most effective techniques to identify abducted children, according to the ministry.Fu, who was named Liu Qiang by his adoptive family in Shijiazhuang, capital of Hebei province, was picked up by his entire family at the railway station in his home city of Jishou, Hunan province."I resolved to find my parents, because I know I was kidnapped, not abandoned," said Fu, 26, a technician in an auto parts company in Tianjin. He remembered one day when he was 4, someone sprayed a substance in front of his face so that he could not open his eyes, and he was taken on a train.Fu left a blood sample with the DNA database in July. One month earlier, his parents had their blood samples taken when police said this could help the search for their son."I prayed to the gods, even in my dreams, to give my son back. He finally returned," said 55-year-old father Fu Gaomao, who was informed on Thursday of the successful match."Abducted children are found matching with their biological parents in the information bank every day," said Zhang Baoyan, founder of Baobeihuijia, or Baby Back Home, a volunteer group that assists in the nationwide search for missing children and offers support to their parents.

WASHINGTON, Aug. 4 (Xinhua) -- U.S. scientists have found two gene mutations occurring in oligodendrogliomas, the second-most common form of brain cancer, according to a study to be published Friday in journal Science.For years scientists have been looking for the primary cancer genes involved in oligodendrogliomas evolvement. Scientists know the two chromosomes held the probable mutations, but the particular gene information remains unclear.Now scientists at Duke University Medical Center and Johns Hopkins University have discovered the most likely genetic mutations that researchers have been hunting for on chromosomes 1 and 19.The genes they identified, CIC or FUBP1, are tumor suppressor genes. The cancer-related pathways that involve these genes could become targets for future treatments, said Hai Yan, a Duke associate professor of pathology and co-corresponding author of the study.The researchers found CIC on chromosome 19 and FUBP1 on chromosome 1 based on an initial study of seven oligodendrogliomas. They found six mutations and two mutations, respectively, in the seven tumors. Further study of 27 more of these tumors showed that there were 12 and three mutations of CIC and FUBP1, respectively. The two genes were rarely mutated in other types of cancers, indicating that they are oligodendroglioma-specific genes.These genes were difficult to find until the technology improved, said Yan."The team used whole genome sequencing technology so that no genes would be excluded, and we found to our surprise that one gene, on chromosome 19, was mutated in six out of the seven initial tumor specimens we sequenced," Yan said. "A mutation frequency of 85 percent is very high."The finding of two additional new genes involved in oligodendrogliomas increases the chances for an effective combination drug therapy for the tumor, Yan said. He envisions a combination cocktail of drugs similar to the combination-drug treatments taken by HIV patients that would target different pathways involved in cancer, and assist both in reducing the chance of relapsing and increasing odds of success.

LOS ANGELES, July 5 (Xinhua) -- NASA's Juno spacecraft is 30 days away before its first launch window opens, the Jet Propulsion Laboratory (JPL) announced on Tuesday."One month from today, our first launch window opens at 11:34 a. m. EDT (8:34 a.m. PDT) and lasts 69 minutes," said Jan Chodas, Juno project manager from NASA's JPL in Pasadena, Los Angeles."Our primary launch period is 22 days long, and so if weather or other issues come up on Aug. 5, we have 21 more days to get Juno flying. Once we get Juno into space, it's a five-year cruise to Jupiter.""The launch window is the length of time allotted every day for an attempt to launch the spacecraft," said Chodas. "The launch period is the period of time in days when everything is in the right place to get your mission off to the right start."For a mission like Juno, getting everything in the right place includes considering the size of the rocket and spacecraft, where our home planet -- and in particular Juno's launch pad -- is pointed at any moment, and its location in space relative to other celestial objects like Juno's final target, Jupiter.Juno is scheduled to launch aboard a United Launch Alliance Atlas V rocket from pad 41-C at the Cape Canaveral Air Force Station, Florida.The solar-powered spacecraft will orbit Jupiter's poles 33 times to find out more about the gas giant's origins, structure, atmosphere and magnetosphere and investigate the existence of a solid planetary core.JPL manages the Juno mission for the principal investigator, Scott Bolton, of Southwest Research Institute in San Antonio.The Juno mission is part of the New Frontiers Program managed at NASA's Marshall Space Flight Center in Huntsville, Alaska. Lockheed Martin Space Systems, Denver, built the spacecraft.

MOSCOW, Aug. 30 (Xinhua) -- Russia's space agency said Tuesday that a Proton-M rocket launch failed earlier this month because of a malfunction in the upper stage.The conclusion was reached by an independent investigation commission following a series of checks, Roscosmos said in a report that was posted on its website."The commission reported that the time span reserved for the gyrostabilized platform's turn was miscalculated and narrowed, which caused the Briz-M upper stage's disorientation and the satellite's journey to a wrong orbit," the agency said.Other systems in the upper stage performed well, the agency said, adding it has lifted a ban on launches of the Proton-M carrier rockets equipped with the Briz-M upper stage.Local media reported the Briz-M, manufactured by the Khrunichev State Research and Production Space Center, has had five failures over its 12-year history of operation.On Aug. 18, a Proton-M carrier rocket failed to deliver a communications satellite into orbit. After the failure, Russia suspended launches of Proton-M rockets pending the outcome of an investigation into the failure.